Saturday, November 19, 2022 9:09:37 AM
Partnership deal(S) with specific terms: IE:
1) Joint partnership clinical trials were? negotiated predicated upon Positive peer reviewed Journal publication.
(Big Pharma with their thousands of CheckPoint Inhibitor Clinical Trials do NEED the much higher response rates which NWBO's technology platform provides:
FUNDING, CASH Infusion and
likely significant equity interest in NWBO at well above Market Prices that
will give Marquee attention and CREDIBILITY VALIDATION to maligned NWBO when that party does with the consent of CEO Linda Powers & Bd of Directors does the ABOVE:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169867409
The above will avoid a threaded, since 2018: Reverse Stock Split, which I never harboured, posted accordingly..... in my reading between the lines of The Grand Strategist CEO Linda Powers who HAS pulled many LARGE Rabbits out of broken Hats since 2018! for all the solely scientific ones based here .
AND should the above transpire:
Presages for UPLISTING!
AND for other Biotech Investors I updated this today which I believe you may find interesting:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170495546
NASA: We are ready for LIFTOFF!
Since Fall of 2019:
Limited to ONE NWBO post daily: Can't reply.
The reason should be apparent to the cognesti to!
DIFFERENT STROKES for DIFFERENT FOLKS.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM